Periprosthetic Knee Infection - Part 2: Treatment.

Rev Bras Ortop (Sao Paulo)

Departamento de Ortopedia e Traumatologia, Hospital Universitário Pedro Ernesto, Rio de Janeiro, RJ, Brasil.

Published: April 2022

Several treatment modalities are proposed for periprosthetic infections, with variable success rates. However, efficacy is related to the appropriate selection of cases for each type of treatment. Debridement with implant retention is indicated in acute infections with fixed implant, and its success depends on the type of infection, comorbidities of the host, and virulence of the etiological agent. One- or two-stage revision is required in cases in which biofilm is forming, or of implant loosening. The choice between performing the review in one or two stages depends on factors such as etiological agent identification, pathogen virulence, local and systemic host factors. Rescue procedures such as arthrodesis, amputation, resection arthroplasty or even antibiotic suppression are reserved for cases in which the infection has not been eradicated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142269PMC
http://dx.doi.org/10.1055/s-0041-1729936DOI Listing

Publication Analysis

Top Keywords

etiological agent
8
periprosthetic knee
4
knee infection
4
infection treatment
4
treatment treatment
4
treatment modalities
4
modalities proposed
4
proposed periprosthetic
4
periprosthetic infections
4
infections variable
4

Similar Publications

Discovery of a Potent Triazole-Based Reversible Targeted Covalent Inhibitor of Cruzipain.

ACS Med Chem Lett

January 2025

Sustainable Chemistry for Metals and Molecules, Department of Chemistry, KU Leuven, Leuven 3000, Belgium.

Cruzipain (CZP) is an essential cysteine protease of , the etiological agent of Chagas disease, and a promising druggable target. To date, no CZP inhibitors have reached clinical use, with research efforts mostly hampered by insufficient potency, limited target selectivity or lack of bioactivity translation from the isolated enzyme to the parasite in cellular environments. In this study, we report the design of , a 1,2,3-triazole-based targeted covalent inhibitor with nanomolar potency (IC = 28 nM) and null inhibition of human cathepsin L.

View Article and Find Full Text PDF

Preventive interventions are expected to substantially improve the prognosis of patients with primary liver cancer, predominantly hepatocellular carcinoma (HCC) and cholangiocarcinoma. HCC prevention is challenging in the face of the evolving etiological landscape, particularly the sharp increase in obesity-associated metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). Next-generation anti-HCV and HBV drugs have substantially reduced, but not eliminated, the risk of HCC and have given way to new challenges in identifying at-risk patients.

View Article and Find Full Text PDF

[Sepsis caused by Pasteurella multocida after a dog bite].

Klin Mikrobiol Infekc Lek

March 2024

Infectious Department, Hospital Agel, Prostejov, Czech Repubic, e-mail:

This article reports a case of systemic infection caused by Pasteurella multocida. The infection was confirmed in a 79-year-old man who was admitted to the hospital after falling from a couch. The disease was manifested by the development of fever, chills, joint pain.

View Article and Find Full Text PDF

Anti-furfurative comparison of Kesh Kanti-Herbal Shampoos and synthetic shampoos against Malassezia furfur for dandruff management.

AMB Express

January 2025

Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Near Bahadrabad, Haridwar, 249405, Uttarakhand, India.

Malassezia furfur is the primary etiological agent of dandruff (Pityriasis capitis). Although herbal shampoos are preferred for their natural, mild ingredients over synthetic counterparts, they are often perceived as less effective in managing flaky scalp conditions or furfuration causing dandruff. The study compares the antifungal efficacy of herbal and synthetic shampoos against M.

View Article and Find Full Text PDF

Erlotinib-induced Perioral Lesions Resembling Scleroderma.

Acta Dermatovenerol Croat

November 2024

Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!